Header Logo

Connection

Wendy Stevens to Anti-HIV Agents

Back to Details
This is a "connection" page, showing publications Wendy Stevens has written about Anti-HIV Agents.
Wendy Stevens
Connection Strength
3,564
Anti-HIV Agents
  1. National Impact of SARS-CoV-2 Infection on HIV Virological Suppression in South Africa. J Acquir Immune Defic Syndr. 2023 12 15; 94(5):381-386.
    View in: PubMed
    Score: 0,473
  2. Diagnosis and monitoring of HIV programmes to support treatment initiation and follow up and improve programme quality. Curr Opin HIV AIDS. 2017 03; 12(2):117-122.
    View in: PubMed
    Score: 0,296
  3. High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen. PLoS One. 2014; 9(5):e97067.
    View in: PubMed
    Score: 0,243
  4. Accumulation of HIV drug resistance mutations in patients failing first-line antiretroviral treatment in South Africa. AIDS Res Hum Retroviruses. 2012 Feb; 28(2):171-5.
    View in: PubMed
    Score: 0,201
  5. Varied patterns of HIV-1 drug resistance on failing first-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr. 2010 Apr 01; 53(4):480-4.
    View in: PubMed
    Score: 0,183
  6. Slow accumulation of HIV resistance mutations: implications for resource-limited settings? J Infect Dis. 2009 Sep 01; 200(5):670-2.
    View in: PubMed
    Score: 0,176
  7. Laboratory monitoring of HIV/AIDS in a resource-poor setting. S Afr Med J. 2003 Apr; 93(4):262-3.
    View in: PubMed
    Score: 0,113
  8. Cohort profile: the South African National Health Laboratory Service (NHLS) National HIV Cohort. BMJ Open. 2022 10 19; 12(10):e066671.
    View in: PubMed
    Score: 0,109
  9. HIV Viral Load Monitoring Among Patients Receiving Antiretroviral Therapy - Eight Sub-Saharan Africa Countries, 2013-2018. MMWR Morb Mortal Wkly Rep. 2021 May 28; 70(21):775-778.
    View in: PubMed
    Score: 0,099
  10. The relative contributions of HIV drug resistance, nonadherence and low-level viremia to viremic episodes on antiretroviral therapy in sub-Saharan Africa. AIDS. 2020 08 01; 34(10):1559-1566.
    View in: PubMed
    Score: 0,094
  11. Moderate Levels of Pre-Treatment HIV-1 Antiretroviral Drug Resistance Detected in the First South African National Survey. PLoS One. 2016; 11(12):e0166305.
    View in: PubMed
    Score: 0,073
  12. Early antiretroviral therapy initiation: access and equity of viral load testing for HIV treatment monitoring. Lancet Infect Dis. 2017 01; 17(1):e26-e29.
    View in: PubMed
    Score: 0,072
  13. Affordable HIV drug-resistance testing for monitoring of antiretroviral therapy in sub-Saharan Africa. Lancet Infect Dis. 2016 Nov; 16(11):e267-e275.
    View in: PubMed
    Score: 0,071
  14. CD4 changes among virologically suppressed patients on antiretroviral therapy: a systematic review and meta-analysis. J Int AIDS Soc. 2015; 18:20061.
    View in: PubMed
    Score: 0,066
  15. High prevalence of the K65R mutation in HIV-1 subtype C infected patients failing tenofovir-based first-line regimens in South Africa. PLoS One. 2015; 10(2):e0118145.
    View in: PubMed
    Score: 0,064
  16. Drug susceptibility and resistance mutations after first-line failure in resource limited settings. Clin Infect Dis. 2014 Sep 01; 59(5):706-15.
    View in: PubMed
    Score: 0,061
  17. HIV-HBV coinfection in Southern Africa and the effect of lamivudine- versus tenofovir-containing cART on HBV outcomes. J Acquir Immune Defic Syndr. 2013 Oct 01; 64(2):174-82.
    View in: PubMed
    Score: 0,058
  18. Use of a prequalification panel for rapid scale-up of high-throughput HIV viral load testing. J Clin Microbiol. 2012 Dec; 50(12):4083-6.
    View in: PubMed
    Score: 0,054
  19. Cost-effectiveness of laboratory monitoring for management of HIV treatment in sub-Saharan Africa: a model-based analysis. AIDS. 2012 Aug 24; 26(13):1663-72.
    View in: PubMed
    Score: 0,054
  20. Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings. AIDS. 2012 Jul 17; 26(11):1345-54.
    View in: PubMed
    Score: 0,054
  21. Antiretroviral therapy interruptions result in loss of protective humoral immunity to neoantigens in HIV-infected individuals. AIDS. 2012 Jul 17; 26(11):1355-62.
    View in: PubMed
    Score: 0,054
  22. Building capacity for the assessment of HIV drug resistance: experiences from the PharmAccess African Studies to Evaluate Resistance network. Clin Infect Dis. 2012 May; 54 Suppl 4:S261-5.
    View in: PubMed
    Score: 0,053
  23. Second-line antiretroviral treatment successfully resuppresses drug-resistant HIV-1 after first-line failure: prospective cohort in Sub-Saharan Africa. J Infect Dis. 2012 Jun; 205(11):1739-44.
    View in: PubMed
    Score: 0,052
  24. Low rates of nucleoside reverse transcriptase inhibitor resistance in a well-monitored cohort in South Africa on antiretroviral therapy. Antivir Ther. 2012; 17(2):313-20.
    View in: PubMed
    Score: 0,051
  25. Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study. Lancet Infect Dis. 2012 Apr; 12(4):307-17.
    View in: PubMed
    Score: 0,051
  26. Increased microbial translocation in = 180 days old perinatally human immunodeficiency virus-positive infants as compared with human immunodeficiency virus-exposed uninfected infants of similar age. Pediatr Infect Dis J. 2011 Oct; 30(10):877-82.
    View in: PubMed
    Score: 0,051
  27. Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. J Acquir Immune Defic Syndr. 2011 Sep 01; 58(1):23-31.
    View in: PubMed
    Score: 0,050
  28. Metabolic and anthropometric parameters contribute to ART-mediated CD4+ T cell recovery in HIV-1-infected individuals: an observational study. J Int AIDS Soc. 2011 Jul 29; 14:37.
    View in: PubMed
    Score: 0,050
  29. HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. Lancet Infect Dis. 2011 Oct; 11(10):750-9.
    View in: PubMed
    Score: 0,050
  30. Randomized trial of time-limited interruptions of protease inhibitor-based antiretroviral therapy (ART) vs. continuous therapy for HIV-1 infection. PLoS One. 2011; 6(6):e21450.
    View in: PubMed
    Score: 0,050
  31. The net cost of incorporating resistance testing into HIV/AIDS treatment in South Africa: a Markov model with primary data. J Int AIDS Soc. 2011 May 15; 14:24.
    View in: PubMed
    Score: 0,049
  32. Transmitted HIV type 1 drug resistance among individuals with recent HIV infection in East and Southern Africa. AIDS Res Hum Retroviruses. 2011 Jan; 27(1):5-12.
    View in: PubMed
    Score: 0,048
  33. Cohort profile: The PharmAccess African (PASER-M) and the TREAT Asia (TASER-M) monitoring studies to evaluate resistance--HIV drug resistance in sub-Saharan Africa and the Asia-Pacific. Int J Epidemiol. 2012 Feb; 41(1):43-54.
    View in: PubMed
    Score: 0,048
  34. HIV-1 drug resistance mutations are present in six percent of persons initiating antiretroviral therapy in Lusaka, Zambia. J Acquir Immune Defic Syndr. 2010 Sep; 55(1):95-101.
    View in: PubMed
    Score: 0,047
  35. A randomized trial of two postexposure prophylaxis regimens to reduce mother-to-child HIV-1 transmission in infants of untreated mothers. AIDS. 2005 Aug 12; 19(12):1289-97.
    View in: PubMed
    Score: 0,033
  36. Evaluation of an oligonucleotide ligation assay for detection of mutations in HIV-1 subtype C individuals who have high level resistance to nucleoside reverse transcriptase inhibitors and non-nucleoside reverse transcriptase inhibitors. J Virol Methods. 2005 May; 125(2):99-109.
    View in: PubMed
    Score: 0,033
  37. Imputing HIV treatment start dates from routine laboratory data in South Africa: a validation study. BMC Health Serv Res. 2017 Jan 17; 17(1):41.
    View in: PubMed
    Score: 0,018
  38. Progress with Scale-Up of HIV Viral Load Monitoring - Seven Sub-Saharan African Countries, January 2015-June 2016. MMWR Morb Mortal Wkly Rep. 2016 Dec 02; 65(47):1332-1335.
    View in: PubMed
    Score: 0,018
  39. Sustainable HIV treatment in Africa through viral-load-informed differentiated care. Nature. 2015 Dec 03; 528(7580):S68-76.
    View in: PubMed
    Score: 0,017
  40. Scale-up of HIV Viral Load Monitoring--Seven Sub-Saharan African Countries. MMWR Morb Mortal Wkly Rep. 2015 Nov 27; 64(46):1287-90.
    View in: PubMed
    Score: 0,017
  41. Time to treatment and patient outcomes among TB suspects screened by a single point-of-care xpert MTB/RIF at a primary care clinic in Johannesburg, South Africa. PLoS One. 2013; 8(6):e65421.
    View in: PubMed
    Score: 0,014
  42. Performance of the PointCare NOW system for CD4 counting in HIV patients based on five independent evaluations. PLoS One. 2012; 7(8):e41166.
    View in: PubMed
    Score: 0,013
  43. HIV-1 phenotypic reverse transcriptase inhibitor drug resistance test interpretation is not dependent on the subtype of the virus backbone. PLoS One. 2012; 7(4):e34708.
    View in: PubMed
    Score: 0,013
  44. Perspectives on introduction and implementation of new point-of-care diagnostic tests. J Infect Dis. 2012 May 15; 205 Suppl 2:S181-90.
    View in: PubMed
    Score: 0,013
  45. Natural killer cell activation distinguishes Mycobacterium tuberculosis-mediated immune reconstitution syndrome from chronic HIV and HIV/MTB coinfection. J Acquir Immune Defic Syndr. 2011 Nov 01; 58(3):309-18.
    View in: PubMed
    Score: 0,013
  46. Estimating the impact of plasma HIV-1 RNA reductions on heterosexual HIV-1 transmission risk. PLoS One. 2010 Sep 13; 5(9):e12598.
    View in: PubMed
    Score: 0,012
  47. Viral genetic determinants of nonprogressive HIV type 1 subtype C infection in antiretroviral drug-naive children. AIDS Res Hum Retroviruses. 2009 Nov; 25(11):1141-8.
    View in: PubMed
    Score: 0,011
  48. Dried fluid spots for HIV type-1 viral load and resistance genotyping: a systematic review. Antivir Ther. 2009; 14(5):619-29.
    View in: PubMed
    Score: 0,010
  49. The status of HIV-1 resistance to antiretroviral drugs in sub-Saharan Africa. Antivir Ther. 2008; 13(5):625-39.
    View in: PubMed
    Score: 0,010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.